BGB-283 Deemed Effective in Phase I Study

2016 Cancer Discovery  
Précis: The differentiation state of KRAS-mutant lung cancer drives MEK inhibitor resistance via distinct pathways of receptor tyrosine kinase activation and confers sensitivity to dual MEK/ FGFR1 blockade in mesenchymal-like cells.
doi:10.1158/2159-8290.cd-nb2016-052 pmid:27267516 fatcat:k4t6l7kbsfbtzpiw2wv6csgyzm